Clinical Trial Update: Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update on neoadjuvant treatment for low HR expression, HER2-negative early breast cancer combining chidamide, PD-1 inhibitor, and pacli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Chidamide (chidamide)
• PACLITAXEL (PACLITAXEL)
• PD-1 inhibitor

Snippet

Sponsor: Sun Yat-sen University | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN